By Karen Raymaakers, About.com Guide
September 3, 2011
FDA has granted fast track approval to Dara BioSciences for their drug KRN5500 which is being used was a treatment for chemotherapy induced neuropathic (nerve) pain (CINP).
KRN5500 is not a narcotic, but it is showing some excellent results in clinical trials. Interestingly, the drug is produced by bacteria called streptomycin alanosinicus. As a result of its effectiveness in relieving pain in patients with CINP, in addition to the extensive need for better options for this common chemotherapy side effect, the FDA will help to speed up the process to getting KRN5500 from the lab into your medicine cabinet.
Some research shows that as many as half of patients who receive chemotherapy will experience CINP, which may go on for many years, or indefinitely following treatment. Neuropathic pain, or nerve pain, is notoriously difficult to manage, and patients who would otherwise go on to lead healthy lives have a decreased quality of life as a result.
http://lymphoma.about.com/b/2011/09/03/fda-fast-tracks-new-drug-for-neuropathic-pain.htm
Acesso em 06 de setembro de 2011.
Nenhum comentário:
Postar um comentário